PLOS ONE | www.plosone.org 1
January 2014 | Volume 9 | Issue 1 | e86616
Towards gender - transformative HIV and TB responses
На пути к гендерно-преобразовательным мерам против ВИЧ и ТБ
12-13 December 2016
Global Action Plan on HIV Drug Resistance - Webinars 12-13 December 2016
The five thematic discussion papers in this collection were prepared by members of the Global Prevention Coalition Steering Group and other experts from various institutions and countries. Contributors are listed in alphabetical order. The five papers are meant to inform country consultations and th...e development of a Global HIV Prevention Roadmap. They do not reflect the views of UNAIDS or any other agency or organization.
more
www.jogh.org • doi: 10.7189/jogh.02.020405 ~ December 2012 • Vol. 2 No. 2 • 020405
Djibuti et al. BMC Public Health (2015) 15:427 DOI 10.1186/s12889-015-1760-z
4th Meeting of NDPHS Expert Group on HIV, TB and AI Oslo, 1-2 March, 2017
Meeting report
Geneva, 16-18 November 2016
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Accessed: 08.10.2019
ECDC Technical Report
In line with ECDC’s recommendations provided in the ’Risk Assessment of HTLV-1/2 transmission by tissue/cell transplantation’ dated 14 March 2012, this Directive replaces the term ‘incidence’ with ‘prevalence’ in the description of endemic areas of HTLV-1/2 i...nfection. According to the new requirements ‘HTLV-1 antibody testing must be performed for donors living in, or originating from high-prevalence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas’ and this applies to both donors of non-reproductive tissues and cells and reproductive cells.
ECDC contracted experts from the Institut Pasteur in Paris to systematically review the published evidence on the distribution of HTLV-1 infection prevalence throughout the world and to identify high-prevalence countries and areas.
more
3rd Edition – July 2017
www.msfaccess.org
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more
The END TB Strategy
Интеграция совместного оказания услуг в связи с ТБ и ВИЧ во всеобъемлющий пакет помощи для потребителей инъекционных наркотиков
Introduction
Accessed 02.03.2020